National Institute for Health and Clinical Excellence (NICE), a special health authority of the National Health Service (NHS), has published positive diagnostics guidance on DySIS Medical's cervical cancer screening product, DySIS colposcopy.
By utilising spectral imaging techniques, DySIS colposcopy maps the condition of a woman's cervix using various colours to indicate normal and abnormal cells, as well as the degree of abnormality present, helping clinicians to take immediate steps to treat patients and prevent disease progression.
Clinical trials conducted on DySIS across Europe, involving hospitals in the UK, Netherlands and Greece, have been shown to boost sensitivity in detecting cervical cancer in its earliest stages.
Recently published results also showed that DySIS helped clinicians identify pre-cancer conditions of cervical cancers in 97% of all cases.
Charles Redman, North Staffs Hospital gynaecological oncologist consultant, said the hospital has made progress in reducing the incidence of cervical cancer in the UK through a good screening programme, but detecting the disease early is still a significant challenge.
"The DySIS instrument uses hi-tech imaging and provides objective measurements that we can use to substantially improve our sensitivity to detecting the disease before it's too late," Redman added.
DySIS is a clinically cost-effective option, compared with standard colposcopy, for examining the uterine cervix in women referred for colposcopy, and should be considered in procurement plans for colposcopy equipment, according to NICE guidance.
DySIS colposcopy has received CE mark and US Food and Drugs Administration approval, according to the company.
Alastair Atkinson, DySIS Medical CEO, said: "This positive guidance recognises the paradigm shift that DySIS can create - helping clinicians to deliver a higher standard of care at a lower overall cost."